

Int'l. Appln. No.: PCT/EP00/05841
Docket No. B45187

17. A composition as claimed in claim 13 wherein the oligonucleotide comprises two CpG dinucleotides.
18. A composition as claimed in claim 13 wherein the CpG oligonucleotide is between 15-45 nucleotides in length.
19. A composition as claimed in claim 13 wherein the CpG oligonucleotide comprises at least one phosphorothioate internucleotide bond.
20. A composition as claimed in claim 13 wherein the oligonucleotide is selected from the group consisting of oligonucleotides designated as WD1001, WD1002, WD1003, WD1004, WD1005, WD1006, and WD1007.
21. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 13 to a patient.
22. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a composition of claim 16 to a patient.
23. A method of producing a composition as claimed in claim 13 comprising admixing a malarial antigen and a CpG immunostimulatory oligonucleotide.
24. A method for the prevention or amelioration of plasmodium infection in a patient, comprising administering an effective amount of a CpG oligonucleotide followed after a suitable time by an effective amount of a malaria antigen.
-